Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ensartinib Food Effect Study in Healthy Volunteers
NCT03510611Phase 1Completed
- Sponsor
- Betta Pharmaceuticals
- Start
- Mar 2018
- Primary completion
- Aug 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of ensartinib in non-small cell lung cancer (NSCLC) (2 arms), sponsored by Betta Pharmaceuticals. Primary endpoints: Peak Plasma Concentration, Area Under the Curve and 2 more. Started Mar 2018; status: completed.
02
Drugs
ensartinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT03510611.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03510611.